Anna Wolska, MS, PhD, FAHA, is a Staff Scientist at the National Heart, Lung, and Blood Institute since September 2014, specializing in research on hyperlipidemia treatments. Wolska holds a distinguished history as a lead researcher and co-inventor of U.S. patents for therapies involving mimetic peptides and apolipoproteins. In addition to a robust research background, Wolska serves as a reviewer for prestigious journals such as the European Heart Journal and the Journal of the American College of Cardiology. Current roles include Communications Officer for the American Association for Clinical Chemistry and Editorial Board Member for the Lipids in Health and Disease journal, alongside hosting a podcast for the Lupus Foundation of America. Wolska's academic credentials include a PhD in Medical Biology, alongside certifications in Laboratory Medicine and Teaching, from Gdański Uniwersytet Medyczny and the University of Gdansk.
Sign up to view 0 direct reports
Get started